The National Cancer Center (NCC) of Japan and Takeda Pharmaceutical Company Limited have signed an agreement with the goal to discover and develop superior, innovative anti-cancer agents originated in Japan.

The objectives of the agreement are to contribute to the development of basic research including studies on pathogenesis and drug susceptibility of cancer by promoting exchanges among researchers, physicians, and others engaged in anti-cancer drug discovery and cancer biology research. Takeda and the NCC have agreed to share information and hold regular discussions in order to collaborate and transition findings from basic research to clinical research and development activities, leveraging the strengths of both parties.

Source: Takeda